Therapy assessment in prostate cancer using choline and PSMA PET/CT.
Eur J Nucl Med Mol Imaging
; 44(Suppl 1): 78-83, 2017 Aug.
Article
em En
| MEDLINE
| ID: mdl-28540419
ABSTRACT
While PET with non-FDG tracers (mainly choline and Ga-PSMA) has commonly been used for restaging in men with biochemically recurrent prostate cancer, as well as for primary staging, it is only recently that a few preliminary studies have addressed the possible use of PET for monitoring the response to systemic therapy of metastatic disease, especially innovative treatments such as abiraterone and enzalutamide. This article aims to evaluate the role of PET imaging with different non-FDG radiotracers for assessment of therapy in advanced prostate cancer patients.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Colina
/
Glutamato Carboxipeptidase II
/
Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada
/
Antígenos de Superfície
Limite:
Humans
/
Male
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article